People: Progenics Pharmaceuticals Inc (PGNX.OQ)

PGNX.OQ on NASDAQ Stock Exchange Global Select Market

7.25USD
19 Dec 2014
Price Change (% chg)

$-0.09 (-1.29%)
Prev Close
$7.34
Open
$7.34
Day's High
$7.56
Day's Low
$7.22
Volume
2,865,053
Avg. Vol
--
52-wk High
--
52-wk Low
--

Search Stocks

Summary

Name Age Since Current Position

Peter Crowley

56 2010 Independent Chairman of the Board

Mark Baker

58 2011 Chief Executive Officer, Director

Robert Israel

57 2013 Executive Vice President - Medical Affairs

John Babich

56 2013 Senior Vice President

Nitya Ray

61 2004 Senior Vice President - Manufacturing

Vivien Wong

57 2013 Senior Vice President - Operations and Portfolio Management

Angelo Lovallo

48 2012 Vice President - Finance, Treasurer

Ann Assumma

60 Vice President - Regulatory Affairs

David Martin

59 General Counsel

Karen Ferrante

56 2014 Independent Director

Michael Kishbauch

65 2013 Independent Director

David Scheinberg

58 1996 Independent Director

Nicole Williams

69 2007 Independent Director

Melissa Downs

2013 IR Contact Officer

Biographies

Name Description

Peter Crowley

Mr. Peter J. Crowley is Independent Chairman of the Board of Progenics Pharmaceuticals Inc. Mr. Crowley is an Operating Partner of MTS Health Partners, L.P., a New York based healthcare merchant bank, and an Operating Partner at JH Partners, a private equity firm. Mr. Crowley retired in 2008 as Managing Director of the Healthcare Investment Banking group at Oppenheimer & Company (formerly CIBC World Markets), which he headed since 1995, with responsibility for public and private financing and advisory services for biotechnology, pharmaceutical, medical device and healthcare services companies. Mr. Crowley serves on the boards of directors of Mount Sinai Hospital, the Foundation Fighting Blindness and Rye Country Day School. He is also a board member at Woodbury Products, a catheter distribution company; Ouidad, a hair salon company; and Napastyle, a specialty food and furnishings company. Mr. Crowley holds an M.B.A. in finance from Columbia University Graduate School of Business and a B.A. in economics from Harvard University.

Mark Baker

Mr. Mark R. Baker, J.D., is Chief Executive Officer, Director of Progenics Pharmaceuticals Inc. Mr. Baker joined the Company in 2005 as Senior Vice President & General Counsel and Secretary. In 2008, he was appointed Executive Vice President – Corporate, in 2009 became President, and has been CEO since March 2011. Prior to joining Progenics, Mr. Baker was Chief Business Officer, Secretary and a director of New York Trans Harbor LLC, a privately-held ferry operation in New York City, and before that Executive Vice President, Chief Legal Officer and Secretary of Continental Grain Company, a privately-held international agri-business and financial concern. Earlier, he was a partner and Co-Chairman of the Capital Markets Group of the New York law firm, Dewey Ballantine. Mr. Baker has an A.B. degree from Columbia College and a J.D. from the Columbia University School of Law.

Robert Israel

Dr. Robert J. Israel, M.D., is Executive Vice President - Medical Affairs of Progenics Pharmaceuticals Inc. Dr. Israel has been with Progenics since 1994. He previously held oncology positions at Sandoz Pharmaceuticals Corporation and Schering-Plough Corporation. Dr. Israel is a licensed physician and is board certified in internal medicine and medical oncology. He received a B.A. in physics from Rutgers University and an M.D. from the University of Pennsylvania, and completed an oncology fellowship at the Memorial Sloan-Kettering Cancer Center. Dr. Israel has been a consultant to the Solid Tumor Service at Sloan-Kettering.

John Babich

Dr. John W. Babich, Ph.D., is Senior Vice President of Progenics Pharmaceuticals Inc. He served as Executive Vice President, Chief Scientific Officer, President of Research and Development and a director of Molecular Insight from 1998 to 2010, and from January to May 2009, as Chairman of the Board and Chief Executive Officer. Prior to founding Molecular Insight, Dr. Babich was Assistant Professor of Radiology at Harvard Medical School and Staff Radiopharmaceutical Chemist at Massachusetts General Hospital, Boston, Massachusetts. Prior to joining MGH, he was Principal Scientist and Head of the Radiopharmaceutical Section at the Institute of Cancer Research in England. Dr. Babich received a B.S. degree in pharmaceutical sciences from St. John's University, an M.S. from the University of Southern California, and a Ph.D. from the University of London.

Nitya Ray

Dr. Nitya G. Ray, Ph.D., is Senior Vice President - Manufacturing of Progenics Pharmaceuticals Inc. He joined the Company in 2001. Prior to joining Progenics, Dr. Ray served as Director of Bioprocess Development at Ortec International, and before that held positions of increasing responsibility at Hoffmann-La Roche in the areas of GMP Manufacturing and Process Development, ultimately as Research Leader, Biopharmaceuticals. Early in his career he developed process technology for biopharmaceutical manufacturing at Verax Corporation. Dr. Ray received an M.S. and Ph.D. in chemical and biochemical engineering from Rutgers University and a B.S. in chemical engineering from Jadavpur University, India.

Vivien Wong

Dr. Vivien Wong, Ph.D., is Senior Vice President - Operations and Portfolio Management of Progenics Pharmaceuticals, Inc. Dr. Wong joined the Company in 2007. Prior to joining Progenics, Dr. Wong was Principal at Theritas Pharmaceutical Consultants from 2004 to 2007. From 1989 to 2004, Dr. Wong held positions of increasing responsibility in preclinical development and pharmacology at Emisphere Technologies, Vivoquest, and Regeneron Pharmaceuticals. She received a B.Sc. in Biology from the Mississippi University for Women, a Ph.D. in Anatomy and Neurobiology from the University of Maryland School of Medicine, and completed a postdoctoral fellowship in Neurology at the Albert Einstein College of Medicine.

Angelo Lovallo

Mr. Angelo W. Lovallo Jr., CPA is Vice President - Finance, Treasurer of Progenics Pharmaceuticals Inc. Before joining Progenics in 2008 as Senior Director, Financial Reporting, he held Vice President, Financial Reporting positions at MBIA Inc. and AllianceBernstein. Earlier in his career, he was in accounting policy at Salomon Smith Barney and a senior manager at KPMG LLP. He received a B.B.A. in public accounting from Hofstra University and is a Certified Public Accountant.

Ann Assumma

Ms. Ann Marie Assumma is Vice President - Regulatory Affairs of Progenics Pharmaceuticals Inc. She has over 30 years' experience in the pharmaceutical industry and regulatory affairs at companies including Dov Pharmaceuticals, Emisphere Technologies, Bayer and American Cyanamid. Ms. Assumma earned her M.S. in pharmacology from New York Medical College and a B.S. in biology from Fordham University.

David Martin

Mr. David E. Martin J.D., is General Counsel of Progenics Pharmaceuticals Inc. He joined Progenics in 2008 as Associate General Counsel after practicing corporate and finance law in New York City for over 25 years including with Loeb & Loeb, AXA Equitable, Dewey Ballantine and in his own special clients practice. He holds a B.A. in mathematics and history from the University of Pennsylvania and a J.D. from the Columbia University School of Law.

Karen Ferrante

Dr. Karen Ferrante, M.D., is Independent Director of Progenics Pharmaceuticals Inc. Dr. Ferrante was appointed head of R&D and chief medical officer of Tokai Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing treatments for prostate cancer and other hormonally driven diseases. From 2007 to 2013, Dr. Ferrante held senior positions at Millennium Pharmaceuticals and its parent company, Takeda Pharmaceuticals, most recently as Oncology Therapeutic Area and Cambridge USA Site Head. From 1999 to 2007, she held positions of increasing responsibility at Pfizer Global Research & Development, culminating as Vice President, Oncology Department. She began her career in the pharmaceutical industry in 1995 as Associate Director of Clinical Oncology at Bristol-Myers Squibb Company. For more than a decade prior, she was at the New England Deaconess Hospital in Boston (Beth Israel Deaconess), where she completed her internship and residency in internal medicine followed by her fellowship in hematology and oncology. While at Beth Israel Deaconess, she served as Instructor, Clinical Instructor and Clinical Fellow in Medicine at the Harvard Medical School, and previously was a Bacteriologist for the City of Providence, Rhode Island Water Supply Board. Dr. Ferrante holds a B.S. in Chemistry and Biology from Providence College and an M.D. from Georgetown University; she has also been an author of a number of papers in the oncology field, is an active participant in academic and professional associations and symposia, and holds several patents.

Michael Kishbauch

Mr. Michael D. Kishbauch has been appointed as Independent Director of Progenics Pharmaceuticals, Inc., with effect from September 11, 2013. Prior to his work at Achillion, Michael founded and served as President and Chief Executive Officer of OraPharma, Inc., which was a publicly traded, commercial-stage pharmaceutical company focused on oral health care. OraPharma was acquired by Johnson & Johnson. Michael previously held senior management positions with MedImmune, Inc.; has held board positions with several other life sciences companies; and continues to serve on Achillion's Board. He holds an M.B.A. from the Wharton School of the University of Pennsylvania and a B.A. in biology from Wesleyan University.

David Scheinberg

Dr. David A. Scheinberg, M.D., Ph.D. is Independent Director of Progenics Pharmaceuticals Inc. Dr. Scheinberg has been a scientific advisor to the company since 1994. Dr. Scheinberg has been associated with the Sloan-Kettering Institute for Cancer Research since 1986, where he is the Vincent Astor Chair and Member, Leukemia Service; Chairman, Molecular Pharmacology and Chemistry Program; Chairman, Experimental Therapeutics Center; and Head, Laboratory of Hematopoietic Cancer Immunochemistry. He also holds the positions of Professor of Medicine and of Pharmacology at the Medical College of Cornell University, and is a Founder and Director of the Tri-Institutional Therapeutics Discovery Institute, a non-profit drug development corporation formed by Sloan-Kettering, Cornell and The Rockefeller University. He received a B.A. from Cornell and an M.D. and a Ph.D. in pharmacology and experimental therapeutics from The Johns Hopkins University School of Medicine. Dr. Scheinberg is a director and member of the audit committee of ContraFect Corporation, a privately-held biotechnology company.

Nicole Williams

Ms. Nicole S. Williams is Independent Director of Progenics Pharmaceuticals Inc. She was elected to the Board in 2007 after retiring as Chief Financial Officer of Abraxis Bioscience Inc., a biopharmaceutical company, and President of its Abraxis Pharmaceutical Products division, positions she assumed upon the 2006 merger of American Pharmaceutical Partners, Inc. and American Bioscience Inc. From 2002 to 2006, Ms. Williams was the Executive Vice President and Chief Financial Officer of American Pharmaceutical Partners, as well as President from 2005. Previously, she was Executive Vice President and Chief Financial Officer of R.P. Scherer, Inc., a global drug delivery company. Ms. Williams is President of the Nicklin Capital Group, Inc., a firm she founded in 1999 to invest in and provide consulting to early-stage technology companies in the Midwest. She is a director, Audit Committee chair and Compensation Committee member at Intercept Pharmaceuticals, Inc., a biotechnology company, and previously held the same positions at Orchid Cellmark, Inc., a leading DNA identity testing service company, until its 2011 purchase by LabCorp. Ms. Williams received her Demi-License en Science Politique from the University of Geneva, Switzerland, her License en Science Politique from the Graduate Institute of International Affairs, University of Geneva, Switzerland and her M.B.A. from the Graduate School of Business, University of Chicago. She is a National Association of Corporate Directors Board Leadership Fellow.

Melissa Downs

Basic Compensation

Options Compensation

Search Stocks